Abstract
Chemotherapy-induced neutropenia (CIN) is a common side effect of anticancer drugs used for treatment of solid tumors. Neutropenic cancer patients are more than 50 times more likely to develop an infection, often bacterial, which can develop febrile neutropenia (FN), a toxicity that requires rigorous treatment. FN is not only potentially life-threatening, but may also alter the patient’s chemotherapy schedule to impact their long-term outcomes. The significant impact of CIN and FN on cancer patients makes it imperative to develop a standardized guideline of prophylactic treatment of CIN. Thus, we conducted a literature review to provide a guideline that compiles guidelines from reputable cancer treatment institutions. Currently, guidelines differ slightly between sources and yet agree upon the vast majority of core practice to ensure the patient safety which we present here to provide as a practice guideline.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30. https://doi.org/10.3322/caac.21332
Miller KD et al (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. https://doi.org/10.3322/caac.21349
US Department of Health and Human Services., N. I. o. H., National Cancer Institute. Common terminology criteria for adverse events (CTCAE). https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-2006-2014_QuickReference_2015x2017.pdf. Accessed 30 Jan 2018
Lyman GH et al (2010) Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 116:5555–5563. https://doi.org/10.1002/cncr.25332
Freifeld AG et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 52:e56–e93. https://doi.org/10.1093/cid/cir073
Chan A, Chen C, Chiang J, Tan SH, Ng R (2012) Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy. Support Care Cancer 20:1525–1532. https://doi.org/10.1007/s00520-011-1241-6
Klastersky J et al (2016) Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol 27:v111–v118. https://doi.org/10.1093/annonc/mdw325
Smith TJ et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33:3199–3212. https://doi.org/10.1200/jco.2015.62.3488
Mousset S et al (2014) Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 93:13–32. https://doi.org/10.1007/s00277-013-1867-1
Truong J, Lee EK, Trudeau ME, Chan KK (2016) Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis. Ann Oncol 27:608–618. https://doi.org/10.1093/annonc/mdv619
Vogel CL et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178–1184. https://doi.org/10.1200/jco.2005.09.102
Coyne CJ et al (2017) Application of the MASCC and CISNE risk-stratification scores to identify low-risk febrile neutropenic patients in the emergency department. Ann Emerg Med 69:755–764. https://doi.org/10.1016/j.annemergmed.2016.11.007
Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12:555–560. https://doi.org/10.1007/s00520-004-0614-5
Flowers CR et al (2013) Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31:794–810. https://doi.org/10.1200/jco.2012.45.8661
Beyar-Katz O et al (2017) Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer. Cochrane Database Syst Rev 6:Cd003914. https://doi.org/10.1002/14651858.CD003914.pub4
Gotzsche PC, Johansen HK (2000) Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database Syst Rev:Cd000026. https://doi.org/10.1002/14651858.cd000026
Hortobagyi GN et al (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375:1738–1748. https://doi.org/10.1056/NEJMoa1609709
Iwata H et al (2017) PALOMA-3: phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that progressed on prior endocrine therapy-safety and efficacy in Asian patients. J Glob Oncol 3:289–303. https://doi.org/10.1200/jgo.2016.008318
RS F et al (2016) PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). J Clin Oncol suppl; abstr 507
Dickler MN et al (2017) MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)/HER2(−) metastatic breast cancer. Clin Cancer Res 23:5218–5224. https://doi.org/10.1158/1078-0432.ccr-17-0754
Goetz MP et al (2017) MONARCH 3: abemaciclib as initial therapy for advanced breast Cancer. J Clin Oncol 35:3638–3646. https://doi.org/10.1200/jco.2017.75.6155
Mullard A (2017) PARP inhibitors plough on. Nat Rev Drug Discov 16:229. https://doi.org/10.1038/nrd.2017.61
Robson M et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377:523–533. https://doi.org/10.1056/NEJMoa1706450
Dockery LE, Gunderson CC, Moore KN (2017) Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer. Onco Targets Ther 10:3029–3037. https://doi.org/10.2147/ott.s114714
Drew Y et al (2016) Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer 114:e21. https://doi.org/10.1038/bjc.2016.133
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Chao, S., Lim, B. (2019). Current Treatment of Febrile Neutropenia. In: De Mello, R., Mountzios, G., Tavares, Á. (eds) International Manual of Oncology Practice. Springer, Cham. https://doi.org/10.1007/978-3-030-16245-0_45
Download citation
DOI: https://doi.org/10.1007/978-3-030-16245-0_45
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-16244-3
Online ISBN: 978-3-030-16245-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)